1 |
Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11, 791-797
DOI
|
2 |
Paisan-Ruiz C, Lewis PA and Singleton AB (2013) LRRK2: cause, risk, and mechanism. J Parkinsons Dis 3, 85-103
DOI
|
3 |
Wang X, Yan MH, Fujioka H et al (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21, 1931-1944
DOI
|
4 |
Orenstein SJ, Kuo SH, Tasset I et al (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16, 394-406
DOI
|
5 |
Parisiadou L, Xie C, Cho HJ et al (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29, 13971-13980
DOI
|
6 |
Martin I, Kim JW, Lee BD et al (2014) Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Cell 157, 472-485
DOI
|
7 |
Trinh J, Guella I and Farrer MJ (2014) Disease penetrance of late-onset parkinsonism: a meta-analysis. JAMA Neurol 71, 1535-1539
DOI
|
8 |
West AB, Moore DJ, Biskup S et al (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102, 16842-16847
DOI
|
9 |
Greggio E, Jain S, Kingsbury A et al (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329-341
DOI
|
10 |
Lee BD, Shin JH, VanKampen J et al (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16, 998-1000
DOI
|
11 |
Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM and Ross CA (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9, 1231-1233
DOI
|
12 |
Shin N, Jeong H, Kwon J et al (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 314, 2055-2065
DOI
|
13 |
West AB, Moore DJ, Choi C et al (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16, 223-232
DOI
|
14 |
Lee BD, Dawson VL and Dawson TM (2012) Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends Pharmacol Sci 33, 365-373
DOI
|
15 |
Biskup S, Moore DJ, Celsi F et al (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60, 557-569
DOI
|
16 |
Piccoli G, Condliffe SB, Bauer M et al (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 31, 2225-2237
DOI
|
17 |
Alegre-Abarrategui J, Christian H, Lufino MM et al (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 18, 4022-4034
DOI
|
18 |
Manzoni C, Denny P, Lovering RC and Lewis PA (2015) Computational analysis of the LRRK2 interactome. PeerJ 3, e778
DOI
|
19 |
Tong Y, Yamaguchi H, Giaime E et al (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107, 9879-9884
DOI
|
20 |
Dodson MW, Zhang T, Jiang C, Chen S and Guo M (2012) Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 21, 1350-1363
DOI
|
21 |
Stenmark H (2009) Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 10, 513-525
DOI
|
22 |
Paisan-Ruiz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600
DOI
|
23 |
Abeliovich A and Gitler AD (2016) Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature 539, 207-216
DOI
|
24 |
Moss J and Bolam JP (2008) A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals. J Neurosci 28, 11221-11230
DOI
|
25 |
Matsuda W, Furuta T, Nakamura KC et al (2009) Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci 29, 444-453
DOI
|
26 |
Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607
DOI
|
27 |
Funayama M, Hasegawa K, Ohta E et al (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57, 918-921
DOI
|
28 |
Nalls MA, Pankratz N, Lill CM et al (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46, 989-993
DOI
|
29 |
Lesage S, Ibanez P, Lohmann E et al (2005) G2019S LRRK2 mutation in french and north african families with Parkinson's disease. Ann Neurol 58, 784-787
DOI
|
30 |
Benamer HT and de Silva R (2010) LRRK2 G2019S in the North African population: a review. Eur Neurol 63, 321-325
DOI
|
31 |
Hutagalung AH and Novick PJ (2011) Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev 91, 119-149
DOI
|
32 |
Beilina A, Rudenko IN, Kaganovich A et al (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A 111, 2626-2631
DOI
|
33 |
Rivero-Rios P, Gomez-Suaga P, Fernandez B et al (2015) Alterations in late endocytic trafficking related to the pathobiology of LRRK2-linked Parkinson's disease. Biochem Soc Trans 43, 390-395
DOI
|
34 |
MacLeod DA, Rhinn H, Kuwahara T et al (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77, 425-439
DOI
|
35 |
Waschbusch D, Michels H, Strassheim S et al (2014) LRRK2 transport is regulated by its novel interacting partner Rab32. PLoS One 9, e111632
DOI
|
36 |
Gomez-Suaga P, Rivero-Rios P, Fdez E et al (2014) LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. Hum Mol Genet 23, 6779-6796
DOI
|
37 |
Heo HY, Kim KS and Seol W (2010) Coordinate regulation of neurite outgrowth by LRRK2 and Its interactor, Rab5. Exp Neurobiol 19, 97-105
DOI
|
38 |
Jeong GR, Jang EH, Bae JR et al (2018) Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. Mol Neurodegener 13, 8
DOI
|
39 |
Steger M, Tonelli F, Ito G et al (2016) Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5, 12813
DOI
|
40 |
Liu Z, Bryant N, Kumaran R et al (2018) LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Hum Mol Genet 27, 385-395
DOI
|
41 |
Purlyte E, Dhekne HS, Sarhan AR et al (2018) Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. EMBO J 37, 1-18
DOI
|
42 |
Steger M, Diez F, Dhekne HS et al (2017) Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife 6, 31012
DOI
|
43 |
Simon-Sanchez J, Schulte C, Bras JM et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41, 1308-1312
DOI
|
44 |
Pihlstrom L, Rengmark A, Bjornara KA et al (2015) Fine mapping and resequencing of the PARK16 locus in Parkinson's disease. J Hum Genet 60, 357-362
DOI
|
45 |
Eguchi T, Kuwahara T, Sakurai M et al (2018) LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc Natl Acad Sci U S A 115, E9115-E9124
DOI
|
46 |
Mazzulli JR, Zunke F, Isacson O, Studer L and Krainc D (2016) alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A 113, 1931-1936
DOI
|
47 |
Cooper AA, Gitler AD, Cashikar A et al (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324-328
DOI
|
48 |
Gitler AD, Bevis BJ, Shorter J et al (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A 105, 145-150
DOI
|
49 |
Dalfo E, Gomez-Isla T, Rosa JL et al (2004) Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. J Neuropathol Exp Neurol 63, 302-313
DOI
|
50 |
Saheki Y and De Camilli P (2012) Synaptic vesicle endocytosis. Cold Spring Harb Perspect Biol 4, a005645
DOI
|
51 |
Matta S, Van Kolen K, da Cunha R et al (2012) LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 75, 1008-1021
DOI
|
52 |
Gallop JL, Jao CC, Kent HM et al (2006) Mechanism of endophilin N-BAR domain-mediated membrane curvature. EMBO J 25, 2898-2910
DOI
|
53 |
Masuda M, Takeda S, Sone M et al (2006) Endophilin BAR domain drives membrane curvature by two newly identified structure-based mechanisms. EMBO J 25, 2889-2897
DOI
|
54 |
Bai J, Hu Z, Dittman JS, Pym EC and Kaplan JM (2010) Endophilin functions as a membrane-bending molecule and is delivered to endocytic zones by exocytosis. Cell 143, 430-441
DOI
|
55 |
Milosevic I, Giovedi S, Lou X et al (2011) Recruitment of endophilin to clathrin-coated pit necks is required for efficient vesicle uncoating after fission. Neuron 72, 587-601
DOI
|
56 |
Ambroso MR, Hegde BG and Langen R (2014) Endophilin A1 induces different membrane shapes using a conformational switch that is regulated by phosphorylation. Proc Natl Acad Sci U S A 111, 6982-6987
DOI
|
57 |
Hill E, van Der Kaay J, Downes CP and Smythe E (2001) The role of dynamin and its binding partners in coated pit invagination and scission. J Cell Biol 152, 309-323
DOI
|
58 |
Verstreken P, Koh TW, Schulze KL et al (2003) Synaptojanin is recruited by endophilin to promote synaptic vesicle uncoating. Neuron 40, 733-748
DOI
|
59 |
Islam MS, Nolte H, Jacob W et al (2016) Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease. Hum Mol Genet 25, 5365-5382
|
60 |
Edvardson S, Cinnamon Y, Ta-Shma A et al (2012) A deleterious mutation in DNAJC6 encoding the neuronalspecific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One 7, e36458
DOI
|
61 |
Koroglu C, Baysal L, Cetinkaya M, Karasoy H and Tolun A (2013) DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat Disord 19, 320-324
DOI
|
62 |
Nguyen M and Krainc D (2018) LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease. Proc Natl Acad Sci U S A 115, 5576-5581
DOI
|
63 |
Belluzzi E, Gonnelli A, Cirnaru MD et al (2016) LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate. Mol Neurodegener 11, 1
DOI
|
64 |
Ryu JK, Jahn R and Yoon TY (2016) Review: Progresses in understanding N-ethylmaleimide sensitive factor (NSF) mediated disassembly of SNARE complexes. Biopolymers 105, 518-531
DOI
|
65 |
Yu RC, Hanson PI, Jahn R and Brunger AT (1998) Structure of the ATP-dependent oligomerization domain of N-ethylmaleimide sensitive factor complexed with ATP. Nat Struct Biol 5, 803-811
DOI
|
66 |
Yun HJ, Park J, Ho DH et al (2013) LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25. Exp Mol Med 45, e36
DOI
|
67 |
Tian JH, Wu ZX, Unzicker M et al (2005) The role of Snapin in neurosecretion: snapin knock-out mice exhibit impaired calcium-dependent exocytosis of large dense-core vesicles in chromaffin cells. J Neurosci 25, 10546-10555
DOI
|
68 |
Shahmoradian SH, Lewis AJ, Genoud C et al (2019) Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nat Neurosci 22, 1099-1109
DOI
|